Huapont Life Sciences Co.,Ltd.

SZSE:002004 Stock Report

Market Cap: CN¥9.0b

Huapont Life SciencesLtd Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Hai An Zhang

Chief executive officer

CN¥1.7m

Total compensation

CEO salary percentagen/a
CEO tenure6.2yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure6.1yrs

Recent management updates

Recent updates

Huapont Life SciencesLtd (SZSE:002004) Might Be Having Difficulty Using Its Capital Effectively

Jun 04
Huapont Life SciencesLtd (SZSE:002004) Might Be Having Difficulty Using Its Capital Effectively

Investors Can Find Comfort In Huapont Life SciencesLtd's (SZSE:002004) Earnings Quality

May 03
Investors Can Find Comfort In Huapont Life SciencesLtd's (SZSE:002004) Earnings Quality

Is Huapont Life SciencesLtd (SZSE:002004) A Risky Investment?

Mar 25
Is Huapont Life SciencesLtd (SZSE:002004) A Risky Investment?

CEO

Hai An Zhang (43 yo)

6.2yrs

Tenure

CN¥1,702,600

Compensation

Mr. Hai An Zhang serves as General Manager since October 29, 2018 & Director since November 16, 2018 at Huapont Life Sciences Co.,Ltd.


Board Members

NamePositionTenureCompensationOwnership
Hai An Zhang
GM & Director6.1yrsCN¥1.70mno data
Rong Wang
Director12.8yrsCN¥1.88m0.55%
CN¥ 49.2m
Zhonghai Liu
Independent Director3.3yrsCN¥142.90kno data
Qiang Bian
Shareholder Supervisor13.3yrsCN¥96.00kno data
Wen Wang
Employee Representative to the Board for Supervisors9.3yrsno datano data
Ming Li
Independent Director3.3yrsCN¥142.90kno data
Zhengjun Wang
Chairman of the Supervisory Board3.3yrsno data0.010%
CN¥ 925.8k

6.1yrs

Average Tenure

52yo

Average Age

Experienced Board: 002004's board of directors are considered experienced (6.1 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 18:42
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Huapont Life Sciences Co.,Ltd. is covered by 12 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peng YanChangjiang Securities Co. LTD.
Pei Hui TangChasing Securities
Bing GaoChina International Capital Corporation Limited